ALX Oncology (ALXO) Projected to Post Quarterly Earnings on Thursday

ALX Oncology (NASDAQ:ALXO - Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.72) per share for the quarter.

ALX Oncology Price Performance

ALXO stock traded up $0.03 during trading on Friday, reaching $1.10. 333,810 shares of the company were exchanged, compared to its average volume of 903,621. The stock's 50 day moving average price is $1.46 and its 200 day moving average price is $1.66. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The company has a market cap of $58.02 million, a P/E ratio of -0.37 and a beta of 0.96. ALX Oncology has a 52-week low of $0.96 and a 52-week high of $17.83.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on ALXO. UBS Group reduced their target price on ALX Oncology from $4.00 to $2.20 and set a "buy" rating on the stock in a research report on Monday, January 27th. HC Wainwright lowered their target price on ALX Oncology from $25.00 to $5.00 and set a "buy" rating for the company in a research note on Friday, January 24th. Cantor Fitzgerald restated an "overweight" rating on shares of ALX Oncology in a research note on Friday, January 24th. Finally, Jefferies Financial Group lowered shares of ALX Oncology from a "buy" rating to a "hold" rating and reduced their target price for the company from $12.00 to $2.00 in a research note on Thursday, December 19th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $3.05.

Remove Ads

Insider Transactions at ALX Oncology

In related news, Director Rekha Hemrajani acquired 30,000 shares of the company's stock in a transaction that occurred on Monday, December 2nd. The stock was acquired at an average price of $1.55 per share, with a total value of $46,500.00. Following the purchase, the director now directly owns 33,000 shares in the company, valued at approximately $51,150. This trade represents a 1,000.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In the last three months, insiders sold 14,443 shares of company stock worth $23,309. 33.40% of the stock is owned by company insiders.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.